SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 & IL21, Induces Localized & Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors October 14, 2021 Cancer, Cell Therapy, Clinical, Immunomodulation View this publication by clicking here.